227 related articles for article (PubMed ID: 34200496)
1. Plasma Proteomic Analysis in Morquio A Disease.
Álvarez JV; Bravo SB; Chantada-Vázquez MP; Barbosa-Gouveia S; Colón C; López-Suarez O; Tomatsu S; Otero-Espinar FJ; Couce ML
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200496
[TBL] [Abstract][Full Text] [Related]
2. Characterization of New Proteomic Biomarker Candidates in Mucopolysaccharidosis Type IVA.
Álvarez VJ; Bravo SB; Chantada-Vazquez MP; Colón C; De Castro MJ; Morales M; Vitoria I; Tomatsu S; Otero-Espinar FJ; Couce ML
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379360
[TBL] [Abstract][Full Text] [Related]
3. Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels.
Dũng VC; Tomatsu S; Montaño AM; Gottesman G; Bober MB; Mackenzie W; Maeda M; Mitchell GA; Suzuki Y; Orii T
Mol Genet Metab; 2013; 110(1-2):129-38. PubMed ID: 23876334
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice.
Dvorak-Ewell M; Wendt D; Hague C; Christianson T; Koppaka V; Crippen D; Kakkis E; Vellard M
PLoS One; 2010 Aug; 5(8):e12194. PubMed ID: 20808938
[TBL] [Abstract][Full Text] [Related]
5. A Case Report of a Japanese Boy with Morquio A Syndrome: Effects of Enzyme Replacement Therapy Initiated at the Age of 24 Months.
Nakamura-Utsunomiya A; Nakamae T; Kagawa R; Karakawa S; Sakata S; Sakura F; Tani C; Matsubara Y; Ishino T; Tajima G; Okada S
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32024277
[TBL] [Abstract][Full Text] [Related]
6. Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome.
Tomatsu S; Sawamoto K; Alméciga-Díaz CJ; Shimada T; Bober MB; Chinen Y; Yabe H; Montaño AM; Giugliani R; Kubaski F; Yasuda E; Rodríguez-López A; Espejo-Mojica AJ; Sánchez OF; Mason RW; Barrera LA; Mackenzie WG; Orii T
Drug Des Devel Ther; 2015; 9():1937-53. PubMed ID: 25897204
[TBL] [Abstract][Full Text] [Related]
7. Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management.
Sawamoto K; Álvarez González JV; Piechnik M; Otero FJ; Couce ML; Suzuki Y; Tomatsu S
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102177
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: early treatment rescues bone lesions?
Tomatsu S; Montaño AM; Oikawa H; Dung VC; Hashimoto A; Oguma T; Gutiérrez ML; Takahashi T; Shimada T; Orii T; Sly WS
Mol Genet Metab; 2015 Feb; 114(2):195-202. PubMed ID: 24953405
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA.
Peracha H; Sawamoto K; Averill L; Kecskemethy H; Theroux M; Thacker M; Nagao K; Pizarro C; Mackenzie W; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Fukao T; Tomatsu S
Mol Genet Metab; 2018 Sep; 125(1-2):18-37. PubMed ID: 29779902
[TBL] [Abstract][Full Text] [Related]
10. Proteomic Analysis in Morquio A Cells Treated with Immobilized Enzymatic Replacement Therapy on Nanostructured Lipid Systems.
Álvarez JV; Bravo SB; García-Vence M; De Castro MJ; Luzardo A; Colón C; Tomatsu S; Otero-Espinar FJ; Couce ML
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540344
[TBL] [Abstract][Full Text] [Related]
11. Elosulfase alfa.
Haddley K
Drugs Today (Barc); 2014 Jul; 50(7):475-83. PubMed ID: 25101330
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy.
Donida B; Marchetti DP; Biancini GB; Deon M; Manini PR; da Rosa HT; Moura DJ; Saffi J; Bender F; Burin MG; Coitinho AS; Giugliani R; Vargas CR
Biochim Biophys Acta; 2015 May; 1852(5):1012-9. PubMed ID: 25701642
[TBL] [Abstract][Full Text] [Related]
13. Development of Substrate Degradation Enzyme Therapy for Mucopolysaccharidosis IVA Murine Model.
Sawamoto K; Tomatsu S
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450640
[TBL] [Abstract][Full Text] [Related]
14. Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).
Lyseng-Williamson KA
BioDrugs; 2014 Oct; 28(5):465-75. PubMed ID: 25200032
[TBL] [Abstract][Full Text] [Related]
15. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment.
Tomatsu S; Montaño AM; Oikawa H; Smith M; Barrera L; Chinen Y; Thacker MM; Mackenzie WG; Suzuki Y; Orii T
Curr Pharm Biotechnol; 2011 Jun; 12(6):931-45. PubMed ID: 21506915
[TBL] [Abstract][Full Text] [Related]
16. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA.
Hendriksz CJ; Harmatz P; Beck M; Jones S; Wood T; Lachman R; Gravance CG; Orii T; Tomatsu S
Mol Genet Metab; 2013; 110(1-2):54-64. PubMed ID: 23665161
[TBL] [Abstract][Full Text] [Related]
17. [Mucopolysaccharidosis IVA (Morquio A syndrome): clinical, biological and therapeutic aspects].
Bouzidi H; Khedhiri S; Laradi S; Ferchichi S; Daudon M; Miled A
Ann Biol Clin (Paris); 2007; 65(1):5-11. PubMed ID: 17264033
[TBL] [Abstract][Full Text] [Related]
18. Biomarker analysis of Morquio syndrome: identification of disease state and drug responsive markers.
Martell L; Lau K; Mei M; Burnett V; Decker C; Foehr ED
Orphanet J Rare Dis; 2011 Dec; 6():84. PubMed ID: 22176730
[TBL] [Abstract][Full Text] [Related]
19. Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatography-tandem mass spectrometry.
Tomatsu S; Montaño AM; Oguma T; Dung VC; Oikawa H; de Carvalho TG; Gutiérrez ML; Yamaguchi S; Suzuki Y; Fukushi M; Kida K; Kubota M; Barrera L; Orii T
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S35-42. PubMed ID: 20107903
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory process and oxidative/nitrative stress: in vivo study in mucopolysaccharidosis type IV A patients under long-term enzyme replacement therapy.
Aguilar Delgado C; Hammerschmidt T; Faverzini JL; Lopes F; Giugliani R; Baldo G; Vargas CR
Arch Biochem Biophys; 2023 Mar; 737():109541. PubMed ID: 36754222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
